H 89 2HCl: Potent and Selective Protein Kinase A Inhibitor for cAMP Pathway Research

Executive Summary: H 89 2HCl is a potent and selective PKA inhibitor (Ki = 48 nM) that distinguishes PKA from related kinases with >10-fold selectivity over PKG and >500-fold over PKC, MLCK, and others (APExBIO). It inhibits cAMP-dependent protein phosphorylation without reducing intracellular cAMP levels, as demonstrated in PC12D pheochromocytoma cells (Wang et al., 2021). H 89 2HCl has been instrumental in elucidating the cAMP/PKA/CREB axis in osteoclastogenesis, neurodegeneration, and cancer models. The compound's high solubility in DMSO (≥51.9 mg/mL) and strict storage requirements (-20°C, solid state) ensure reproducible results. It is supplied by APExBIO for research use only, not for diagnostic or medical applications.

Biological Rationale

Protein kinase A (PKA) is a central mediator of cAMP-dependent signal transduction. It regulates gene expression, metabolism, and cytoskeletal dynamics in diverse cell types (Wang et al., 2021). Dysregulation of the cAMP/PKA pathway is implicated in neurodegenerative diseases, cancer, and abnormal bone remodeling. Pharmacological inhibition of PKA offers a means to dissect signaling specificity in these contexts.

H 89 2HCl (N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide dihydrochloride) was developed to provide selective, potent inhibition of PKA catalytic activity, while minimizing off-target effects on other kinases (APExBIO). Its selectivity profile and physicochemical properties make it a reference tool for mapping cAMP/PKA-dependent pathways in cellular and animal models.

Mechanism of Action of H 89 2HCl

H 89 2HCl acts as a competitive inhibitor at the ATP-binding site of the PKA catalytic subunit. The compound's Ki for PKA is 48 nM in cell-free kinase assays (APExBIO), supporting its high potency. Selectivity profiling shows:

• ~10-fold preference for PKA over protein kinase G (PKG)
• >500-fold selectivity over PKC, MLCK, calmodulin kinase II, and casein kinase I/II
• H 89 2HCl also inhibits S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b, but with higher IC50 values (80–2800 nM)

In cellular studies, H 89 2HCl suppresses cAMP-dependent phosphorylation events without altering intracellular cAMP concentrations. In PC12D cells, it dose-dependently blocks forskolin-induced neurite outgrowth and histone IIb phosphorylation (Wang et al., 2021). In animal models, it modulates cAMP/PKA pathway activity, providing a functional readout of signaling inhibition.

Evidence & Benchmarks

• H 89 2HCl inhibits PKA with a Ki of 48 nM in cell-free enzyme assays (APExBIO).
• Shows approximately 10-fold selectivity for PKA over PKG and >500-fold over PKC, MLCK, calmodulin kinase II, and casein kinase I/II (APExBIO).
• Inhibits S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b with IC50 values between 80 nM and 2800 nM (APExBIO).
• Does not reduce intracellular cAMP levels, but blocks cAMP/PKA-dependent phosphorylation (Wang et al., Figure 2, https://doi.org/10.1016/j.cellsig.2020.109847).
• Suppresses forskolin-induced neurite outgrowth and histone IIb phosphorylation dose-dependently in PC12D cells (Wang et al., Figure 3, https://doi.org/10.1016/j.cellsig.2020.109847).
• Soluble at ≥51.9 mg/mL in DMSO, but insoluble in water and ethanol (APExBIO product documentation: https://www.apexbt.com/h-89-2hcl.html).
• Recommended storage as solid at -20°C. Solutions should be used promptly to avoid degradation (APExBIO).

Compared to H 89 2HCl: Potent PKA Inhibitor for Advanced cAMP Pathway..., this article provides a structured update on quantitative benchmarks and selectivity metrics based on recent peer-reviewed evidence. For more mechanistic insights, see Advanced Insights into PKA Inhibition and Bone Remodeling, which integrates neural regulation aspects. For a broader perspective on cAMP pathway interrogation, refer to Potent and Selective PKA Inhibitor for cAMP Pathway Models; the present article clarifies selectivity boundaries and new storage guidelines.

Applications, Limits & Misconceptions

H 89 2HCl is a standard tool for:

• Dissecting cAMP/PKA signaling in neurodegeneration, bone metabolism, and cancer research (Wang et al., 2021).
• Validating the role of PKA in CREB phosphorylation and downstream gene expression.
• Studying cAMP/PKA/CREB axis in osteoclastogenesis and bone remodeling.
• Modulating protein phosphorylation in animal models with defined selectivity.

Common Pitfalls or Misconceptions

• H 89 2HCl is not exclusively selective for PKA at higher concentrations; off-target effects on S6K1, MSK1, and others may occur above 100 nM (APExBIO).
• The compound does not lower intracellular cAMP; it inhibits PKA activity downstream (Wang et al., 2021).
• It is not suitable for diagnostic or therapeutic use; for research use only (APExBIO).
• Water or ethanol solubilization is not recommended due to insolubility; use DMSO only (APExBIO).
• Degradation can occur in solution at room temperature; aliquot and store at -20°C (APExBIO).

Workflow Integration & Parameters

For optimal experimental outcomes:

• Prepare fresh stock solutions in DMSO at ≥51.9 mg/mL; avoid repeated freeze-thaw cycles.
• Store solid material at -20°C in a desiccated environment.
• Use working solutions promptly; do not store in solution for extended periods.
• Apply concentrations ≤100 nM for maximal PKA selectivity in cellular assays.
• Always include vehicle (DMSO) controls in design.

The B2190 kit from APExBIO provides validated quality and reliable documentation for scientists.

Conclusion & Outlook

H 89 2HCl remains a reference standard for selective PKA inhibition in cAMP pathway research. Its well-characterized selectivity and reproducible performance enable robust dissection of signaling events across neurobiology, bone biology, and oncology. Ongoing improvements in selectivity profiling and application protocols may further extend its utility. For up-to-date technical details, consult the official APExBIO H 89 2HCl product page and recent peer-reviewed literature.